BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...Its lead program is slated to enter the clinic in 2H21, according to President and CEO Geno...
BioCentury | Aug 14, 2018
Company News

Management tracks: Cheng departing Gilead as CMO

...director at Astellas Pharma Inc. (Tokyo:4503). Cancer company Elucida Oncology Inc. (New York, N.Y.) hired Geno...
BioCentury | Mar 2, 2018
Company News

Medicines Co. board could tilt toward Denner’s control

...company plans to nominate at the meeting are Denner, Medicines Co. Executive Chairman Fredric Eshelman, Geno...
BioCentury | Apr 21, 2017
Company News

NantWorks, Genos deal

NantWorks’ molecular diagnostics subsidiary NantOmics Inc. will acquire next-generation sequencing and consumer genomics company Genos for an undisclosed amount. NantOmics will gain Genos’s crowdsourced platforms for genomics research and discovery. Previously, NantOmics invested $6 million...
BioCentury | Mar 13, 2017
Company News

Management tracks

...return to the CEO role in 3Q17. Synthetic biology company Intrexon Corp. (NYSE:XON) said President Geno...
BioCentury | Jun 20, 2016
Product Development

Predictive potential

...CytoploRare from Geno Biotech Co. Ltd. is the first circulating tumor cell test approved in China...
...decisions, particularly in populations with limited access to targeted therapies. CEO Wei He told BioCentury Geno...
...anaplastic lymphoma kinase (ALK) from Pfizer Inc. Geno plans to report those data this year. Geno...
BioCentury | May 18, 2016
Company News

Management tracks

...and administrative officer at Ariad Pharmaceuticals Inc. (NASDAQ:ARIA). Synthetic biology company Intrexon Corp. (NYSE:XON) named Geno...
BioCentury | Feb 9, 2016
Company News

Pfizer unveils post-merger management team

...will become GIP Group President and lead the combined team. Current Group President of GIP Geno...
BioCentury | Jun 8, 2015
Financial News

Genovis completes rights offering

...Genovis AB (SSE:GENO), Lund, Sweden Business: Supply/Service Date completed: 2015-06-04 Type: Rights offering Raised: SEK14.6 million...
BioCentury | May 5, 2015
Company News

Management tracks

...resigned. Michael Bruch, the company's controller, will be interim CFO. Biochemical supply company Genovis AB (SSE:GENO...
Items per page:
1 - 10 of 47
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...Its lead program is slated to enter the clinic in 2H21, according to President and CEO Geno...
BioCentury | Aug 14, 2018
Company News

Management tracks: Cheng departing Gilead as CMO

...director at Astellas Pharma Inc. (Tokyo:4503). Cancer company Elucida Oncology Inc. (New York, N.Y.) hired Geno...
BioCentury | Mar 2, 2018
Company News

Medicines Co. board could tilt toward Denner’s control

...company plans to nominate at the meeting are Denner, Medicines Co. Executive Chairman Fredric Eshelman, Geno...
BioCentury | Apr 21, 2017
Company News

NantWorks, Genos deal

NantWorks’ molecular diagnostics subsidiary NantOmics Inc. will acquire next-generation sequencing and consumer genomics company Genos for an undisclosed amount. NantOmics will gain Genos’s crowdsourced platforms for genomics research and discovery. Previously, NantOmics invested $6 million...
BioCentury | Mar 13, 2017
Company News

Management tracks

...return to the CEO role in 3Q17. Synthetic biology company Intrexon Corp. (NYSE:XON) said President Geno...
BioCentury | Jun 20, 2016
Product Development

Predictive potential

...CytoploRare from Geno Biotech Co. Ltd. is the first circulating tumor cell test approved in China...
...decisions, particularly in populations with limited access to targeted therapies. CEO Wei He told BioCentury Geno...
...anaplastic lymphoma kinase (ALK) from Pfizer Inc. Geno plans to report those data this year. Geno...
BioCentury | May 18, 2016
Company News

Management tracks

...and administrative officer at Ariad Pharmaceuticals Inc. (NASDAQ:ARIA). Synthetic biology company Intrexon Corp. (NYSE:XON) named Geno...
BioCentury | Feb 9, 2016
Company News

Pfizer unveils post-merger management team

...will become GIP Group President and lead the combined team. Current Group President of GIP Geno...
BioCentury | Jun 8, 2015
Financial News

Genovis completes rights offering

...Genovis AB (SSE:GENO), Lund, Sweden Business: Supply/Service Date completed: 2015-06-04 Type: Rights offering Raised: SEK14.6 million...
BioCentury | May 5, 2015
Company News

Management tracks

...resigned. Michael Bruch, the company's controller, will be interim CFO. Biochemical supply company Genovis AB (SSE:GENO...
Items per page:
1 - 10 of 47